Pediatric Survivorship: Considerations Following CAR T-Cell Therapy.

BACKGROUND

This article presents an overview of pediatric relapsed and refractory acute lymphoblastic leukemia (ALL) and chimeric antigen receptor (CAR) T-cell therapy in pediatric patients.

OBJECTIVES

Acute and chronic post-CAR T-cell effects and considerations are discussed, along with survivorship considerations.

METHODS

A case study illustrates the identification and management of physiologic and psychosocial sequelae.

FINDINGS: B-cell aplasia, hypogammaglobulinemia, infections, and cumulative effects of CAR T-cell therapy and other treatments are a concern in the pediatric population. Unique to pediatric and young adult survivors of childbearing potential are implications for post-treatment fertility. Financial toxicities and psychosocial needs require a family-centered approach to interventions that address the impact of CAR T-cell therapy not only on the patient, but also on caregivers and siblings.